Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Retained Earnings · Q4 FY2025 · quarter ended Dec 2025
Retained earnings rises 37.3% from a year ago
Retained earnings stood at $23.58M at the end of Q4 FY2025, up 37.3% from a year earlier. Over 3 fiscal years it compounded at +23.4% a year.
Context
- Retained earnings amounted to 78.0% of total assets at the end of Q4 FY2025, down 12.8 pp from a year earlier.
- Retained earnings increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps rising in the next quarterly balance sheet after a +37.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- 23.58M USD
- Year-over-year change
- +37.3%
- 4-year CAGR
- +74.6%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.58M | +37.3% |
| FY2024 | 2024-12-31 | 17.17M | +16.0% |
| FY2023 | 2023-12-31 | 14.8M | +18.0% |
| FY2022 | 2022-12-31 | 12.55M | +394.8% |
| FY2021 | 2021-12-31 | 2.54M | — |
Retained Earnings vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +37.3% is the highest of 10, against a peer median of -7.4%.
- Retained earnings amounts to 78.0% of total assets for NNNN, versus a peer median of 185.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $23.58M USD | +37.3% | +23.4% | 78.0% |
| Mar 2026 | -$226.46M USD | -14.7% | — | 242.4% | |
| Mar 2026 | -$267.75M USD | +0.4% | — | 196.6% | |
| Feb 2026 | -$454.53M USD | -7.4% | — | 174.4% | |
| Mar 2026 | -$731.39M USD | -32.4% | — | 137.5% | |
| Dec 2025 | -$762.69M USD | — | — | 227.4% | |
| Mar 2026 | -$774.8M USD | -10.6% | — | 73.8% | |
| Mar 2026 | -$1.01B USD | +26.4% | — | 201.0% | |
| Mar 2026 | -CA$1.28B CAD | +1.6% | — | 97.6% | |
| Mar 2026 | -$1.49B USD | -13.8% | — | 1152.5% | |
| Mar 2026 | -$3.63B USD | +11.4% | — | 27.5% | |
| Peer median (excluding NNNN) | — | -7.4% | — | 185.5% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.